Cardiotoxicity and peri‐operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T‐cell therapy: a narrative review

Anaesthesia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Summary Introduction Immunotherapy has transformed cancer treatment, particularly with immune checkpoint inhibitors and chimeric antigen receptor T‐cell therapy. Despite their efficacy, these therapies can induce cardiotoxicity, presenting significant clinical challenges. Immune cause myocarditis; pericarditis; arrhythmias; myocardial infarction through immune‐mediated inflammation. Chimeric therapy may result in cardiovascular complications due to cytokine release syndrome, including dysfunction, endothelial damage arrhythmias. Methods We used PubMed, Embase Google Scholar search for peer‐reviewed articles September 2024 without setting any date limits. Our selection criteria encompassed studies focusing on cardiotoxicity related or therapy, comprising original research, meta‐analyses, trials review articles. The findings were reported narratively. Results Early diagnosis of is critical but challenging non‐specific symptoms. Diagnostic tools include ECG; cardiac biomarkers; echocardiography; magnetic resonance imaging; endomyocardial biopsy. However, no single tool definitive. High‐dose corticosteroids are the first‐line treatment inhibitor‐induced myocarditis, additional immunosuppressive refractory cases. Standard heart failure management protocols should be followed cases failure. Tocilizumab utilised therapy‐induced alongside supportive care, fluid resuscitation vasopressors severe Discussion As use immunotherapy expands, understanding mechanisms, risk factors strategies increasingly important. Collaborative efforts among oncologists, cardiologists anaesthetists essential mitigate risks, especially peri‐operative settings. Ongoing research vital improve safe effective immunotherapeutic drugs while minimising adverse effects.

Language: Английский

Quelle place pour la néphrectomie dite de cytoréduction dans le cancer du rein au stade métastatique en 2025 ?

Progrès en Urologie - FMC, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Impact of Preoperative Systemic Therapy on Cytoreductive Nephrectomy Outcomes in the National Surgical Quality Improvement Program (NSQIP)

Clinical Genitourinary Cancer, Journal Year: 2024, Volume and Issue: 23(1), P. 102258 - 102258

Published: Nov. 1, 2024

Language: Английский